Send me real-time posts from this site at my email

Watchlist Update Sept 10 : Aurinia Pharma - Analyst Comments

TIGER'S TAKE:   On our trading list, a promising junior biotech stock. Their drug for lupus nephritis is extremely promising.   $AUPH

Aurinia Pharmaceuticals initiated with an Outperform at Oppenheimer

Oppenheimer analyst Justin Kim initiated Aurinia Pharmaceuticals with an Outperform rating and $14 price target, citing his view that lead asset voclosporin could become the first therapeutic approved for treatment of lupus nephritis.

Source: (

$AUPH, Aurinia Pharmaceuticals Inc / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.

*   NOTE:   As with all biotech stocks this is not without above average risk....   *

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue